Table 2. Selected trials of adjuvant immunotherapy for NSCLC.
| Trial identifier | Phase | Sponsor | Stage | Intervention | Primary endpoint |
|---|---|---|---|---|---|
| NCT02595944 | 3 | National Cancer Institute (NCI) | IB–IIIA | Nivolumab | DFS, OS |
| NCT02486718 | 3 | Hoffmann-La Roche | IB–IIIA | Atezolizumab | DFS |
| NCT02273375 | 3 | Canadian Cancers Trials Group | IB-IIIA | Durvalumab | DFS |
| NCT03130764 | 2 | Columbia University | IB–IIIA | Durvalumab and Tremelimumab | Induced T-cell response rate |
| NCT02504372 | 3 | EORTC, Merck | IB–IIIA | Pembrolizumab | DFS |
| NCT03053856 | 2 | Samsung Medical Center | IIIA (N2) | Pembrolizumab | DFS |
NSCLC, non-small cell lung cancer; DFS, disease free survival. OS, overall survival. EORTC, European Organisation for Research and Treatment of Cancer.